about
Addition of drug/s to a chemotherapy regimen for metastatic breast cancerChemotherapy alone versus endocrine therapy alone for metastatic breast cancerMeta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancerSystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesUnliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpointA comparative analysis on the efficacy and safety of intaxel® and taxol® in advanced metastatic breast cancer.Comparing medical cost of care for patients with metastatic breast cancer receiving taxane therapy: claims analysis.Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198.Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?A systematic review of taxane-containing regimens for metastatic breast cancer.Comparative analysis of xanafide cytotoxicity in breast cancer cell lines.Past, present, and future challenges in breast cancer treatment.Weekly docetaxel in the treatment of metastatic breast cancer.Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneOptimal use of taxanes in metastatic breast cancerDisparities in Breast Cancer: Private Patients Have Better Outcomes Than Public Patients.Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation.
P2860
Q24236594-45EC13FF-1BB8-4939-8436-1D4E8A23554BQ24248696-C766568D-D504-4248-A1D2-0155F8521B48Q26860469-F1B9667B-707B-410A-9747-2087176908C8Q28080469-9C0E35DE-BBD7-4637-BF88-D92E60B84789Q30560953-1DAD48E6-2D32-4A89-9378-DE4A8E7516E7Q33409451-CA119704-FDDB-49F7-8CC0-F298D20E5271Q33932401-2D3950A0-29EC-4F3A-BCD2-269A2FE76563Q35037923-1A568FDA-B509-47B6-8B4B-01C4B88BF79AQ35815486-C9AB24EC-FF26-45AB-ADED-C2F81C02F3E2Q36211570-29864970-704F-48CA-B1F4-01364B481959Q36608659-EB06C0AE-E9C0-4E2E-90E0-E6E9819068A7Q36934273-CCDE75C8-35A8-4857-9235-E60C722398DDQ37052871-23235B89-87A5-47BF-A9E2-70C96E160522Q37152795-A25E2618-406D-4CC8-AA1A-3B30B8E8FDE2Q37225780-2A9565F1-F717-4987-8396-CE39F8CEBEEFQ38618874-A7BDFC70-124B-4916-89D0-5961CA3219BFQ51888144-522D1EC5-C534-402F-B692-DD1E13BA7159
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Taxane containing regimens for metastatic breast cancer
@ast
Taxane containing regimens for metastatic breast cancer
@en
Taxane containing regimens for metastatic breast cancer
@en-gb
Taxane containing regimens for metastatic breast cancer
@nl
type
label
Taxane containing regimens for metastatic breast cancer
@ast
Taxane containing regimens for metastatic breast cancer
@en
Taxane containing regimens for metastatic breast cancer
@en-gb
Taxane containing regimens for metastatic breast cancer
@nl
prefLabel
Taxane containing regimens for metastatic breast cancer
@ast
Taxane containing regimens for metastatic breast cancer
@en
Taxane containing regimens for metastatic breast cancer
@en-gb
Taxane containing regimens for metastatic breast cancer
@nl
P2860
P1476
Taxane containing regimens for metastatic breast cancer
@en
P2093
Emma Donoghue
John Simes
P2860
P356
10.1002/14651858.CD003366.PUB2
P577
2005-04-20T00:00:00Z